Serotonin receptors in depression: from A to B
- PMID: 28232871
- PMCID: PMC5302148
- DOI: 10.12688/f1000research.9736.1
Serotonin receptors in depression: from A to B
Abstract
The role of serotonin in major depressive disorder (MDD) is the focus of accumulating clinical and preclinical research. The results of these studies reflect the complexity of serotonin signaling through many receptors, in a large number of brain regions, and throughout the lifespan. The role of the serotonin transporter in MDD has been highlighted in gene by environment association studies as well as its role as a critical player in the mechanism of the most effective antidepressant treatments - selective serotonin reuptake inhibitors. While the majority of the 15 known receptors for serotonin have been implicated in depression or depressive-like behavior, the serotonin 1A (5-HT 1A) and 1B (5-HT 1B) receptors are among the most studied. Human brain imaging and genetic studies point to the involvement of 5-HT 1A and 5-HT 1B receptors in MDD and the response to antidepressant treatment. In rodents, the availability of tissue-specific and inducible knockout mouse lines has made possible the identification of the involvement of 5-HT 1A and 5-HT 1B receptors throughout development and in a cell-type specific manner. This, and other preclinical pharmacology work, shows that autoreceptor and heteroreceptor populations of these receptors have divergent roles in modulating depression-related behavior as well as responses to antidepressants and also have different functions during early postnatal development compared to during adulthood.
Keywords: 5-HT1A; 5-HT1B; 5-HTT; MDD; antidepressant; major depressive disorder; selective serotonin reuptake inhibitors; serotonin; serotonin receptor.
Conflict of interest statement
Competing interests: The authors declare that they have no competing interests.No competing interests were disclosed.No competing interests were disclosed.No competing interests were disclosed.
Figures


Similar articles
-
Antidepressants for the treatment of depression in people with cancer.Cochrane Database Syst Rev. 2018 Apr 23;4(4):CD011006. doi: 10.1002/14651858.CD011006.pub3. Cochrane Database Syst Rev. 2018. Update in: Cochrane Database Syst Rev. 2023 Mar 31;3:CD011006. doi: 10.1002/14651858.CD011006.pub4. PMID: 29683474 Free PMC article. Updated.
-
Omega-3 fatty acids for depression in adults.Cochrane Database Syst Rev. 2021 Nov 24;11(11):CD004692. doi: 10.1002/14651858.CD004692.pub5. Cochrane Database Syst Rev. 2021. PMID: 34817851 Free PMC article.
-
Antidepressants versus placebo for panic disorder in adults.Cochrane Database Syst Rev. 2018 Apr 5;4(4):CD010676. doi: 10.1002/14651858.CD010676.pub2. Cochrane Database Syst Rev. 2018. PMID: 29620793 Free PMC article.
-
Psychological therapies for treatment-resistant depression in adults.Cochrane Database Syst Rev. 2018 May 14;5(5):CD010558. doi: 10.1002/14651858.CD010558.pub2. Cochrane Database Syst Rev. 2018. PMID: 29761488 Free PMC article.
-
Cost-effectiveness of using prognostic information to select women with breast cancer for adjuvant systemic therapy.Health Technol Assess. 2006 Sep;10(34):iii-iv, ix-xi, 1-204. doi: 10.3310/hta10340. Health Technol Assess. 2006. PMID: 16959170
Cited by
-
Anxiolytic effect of zinc oxide gallic acid composite nanoparticles following D-galactose administration in rats.Sci Rep. 2025 Jul 21;15(1):26410. doi: 10.1038/s41598-025-08014-1. Sci Rep. 2025. PMID: 40691168 Free PMC article.
-
Functional Dimerization of Serotonin Receptors: Role in Health and Depressive Disorders.Int J Mol Sci. 2023 Nov 16;24(22):16416. doi: 10.3390/ijms242216416. Int J Mol Sci. 2023. PMID: 38003611 Free PMC article. Review.
-
The Triple Combination Phentermine Plus 5-HTP/Carbidopa Leads to Greater Weight Loss, With Fewer Psychomotor Side Effects Than Each Drug Alone.Front Pharmacol. 2019 Nov 6;10:1327. doi: 10.3389/fphar.2019.01327. eCollection 2019. Front Pharmacol. 2019. PMID: 31780943 Free PMC article.
-
Therapeutic Potential of Curcumin in Reversing the Depression and Associated Pseudodementia via Modulating Stress Hormone, Hippocampal Neurotransmitters, and BDNF Levels in Rats.Neurochem Res. 2021 Dec;46(12):3273-3285. doi: 10.1007/s11064-021-03430-x. Epub 2021 Aug 18. Neurochem Res. 2021. PMID: 34409523
-
Altered Serotonin 1B Receptor Binding After Escitalopram for Depression Is Correlated With Treatment Effect.Int J Neuropsychopharmacol. 2024 May 1;27(5):pyae021. doi: 10.1093/ijnp/pyae021. Int J Neuropsychopharmacol. 2024. PMID: 38695786 Free PMC article.
References
-
- De Montigny C: Enhancement of the 5-HT neurotransmission by antidepressant treatments. J Physiol (Paris). 1981;77(2–3):455–61. - PubMed
-
- Messing RB, Phebus L, Fisher LA, et al. : Analgesic effect of fluoxetine hydrochloride (Lilly 110140), a specific inhibitor of serotonin uptake. Psychopharmacol Commun. 1975;1(5):511–21. - PubMed
Publication types
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources